array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2511) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(67) "Gene Therapy Market Forecasted to Surpass USD 38.33 Billion by 2030" ["snippet_en"]=> string(280) "The Gene Therapy Market exhibited substantial growth, reaching USD 9.42 Billion in 2023 and is anticipated to escalate to USD 38.33 Billion by 2030. This growth trajectory signifies a robust compound annual growth rate (CAGR) of 22.2% during the forecast period from 2023 to 2030." ["url"]=> string(126) "https://www.whatech.com/og/markets-research/medical/811369-gene-therapy-market-forecasted-to-surpass-usd-38-33-billion-by-2030" ["image_url"]=> NULL ["source"]=> string(11) "whatech.com" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(15) "Market Movement" } } [1]=> array(7) { ["title_en"]=> string(101) "Vislink Reports Fourth Quarter and Full Year 2023 Financial and Operational Results | VISL Stock News" ["snippet_en"]=> string(296) "Vislink Technologies, Inc. reports 75% year-over-year revenue growth in MilGov markets for 2023 and forecasts improved cash flow and significant revenue expansion in 2024. The company achieved key milestones such as acquiring Broadcast Microwave Services, launching Air-to-AnywhereTM, solidifying" ["url"]=> string(118) "https://www.stocktitan.net/news/VISL/vislink-reports-fourth-quarter-and-full-year-2023-financial-and-j0p89330ku8z.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3f8e49fe-ac85-4e30-b734-612d0ac95482" ["source"]=> string(14) "stocktitan.net" ["publication_date"]=> string(10) "2024-03-28" ["categories"]=> array(4) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(11) "Acquisition" [3]=> string(18) "Expansion & Growth" } } [2]=> array(7) { ["title_en"]=> string(141) "Toptech is starting to ‘break away from low PBR’… “Prepared for KRW 1 trillion in sales with BMS, dividend payout ratio set at 20%”" ["snippet_en"]=> string(356) "“Toptech will reorganize its business structure into BMS (Battery, Mobility, Smart Factory). “We are developing four new products this year, and our goal is to achieve stable sales of 1 trillion won.” Toptech CEO Jeong Ji-yong met with the Kookmin Ilbo at the Asan plant in South Chungcheong Province on the 5th and expressed his ambition. Toptech is" ["url"]=> string(50) "https://m.kmib.co.kr/view_amp.asp?arcid=0019904883" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c0c6c198-a46a-4359-b1d7-b01a8de58f2b" ["source"]=> string(10) "kmib.co.kr" ["publication_date"]=> string(10) "2024-03-01" ["categories"]=> array(3) { [0]=> string(18) "Business Structure" [1]=> string(5) "Award" [2]=> string(24) "Quarterly/Annual Figures" } } [3]=> array(7) { ["title_en"]=> string(76) "Futures Flat After OpenAI "Train Wreck" As Markets Brace For Nvidia Earnings" ["snippet_en"]=> string(83) "ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero" ["url"]=> string(101) "https://www.zerohedge.com/markets/futures-flat-after-openai-train-wreck-markets-brace-nvidia-earnings" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b13dbd9f-8a79-4ebc-93dc-f64dea8ed47c" ["source"]=> string(13) "zerohedge.com" ["publication_date"]=> string(10) "2023-11-20" ["categories"]=> array(3) { [0]=> string(18) "General Investment" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Quarterly/Annual Figures" } } [4]=> array(7) { ["title_en"]=> string(125) "What are the benefits of product diversification? Bristol-Myers Squibb’s third quarterly report is a textbook demonstration" ["snippet_en"]=> string(445) "Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest healthcare companies. Although it has faced various adverse factors in recent years, such as the loss of market share of its best-selling drug Revlimid and other products, it has still achieved growth and product diversification. Bristol-Myers Squibb's latest quarterly report also proved once again that investors don't need to worry too much about the risks of this medical stock." ["url"]=> string(188) "https://nai500.com/zh-hant/blog/2023/11/%E7%94%A2%E5%93%81%E5%A4%9A%E5%85%83%E5%8C%96-%E5%A5%BD%E8%99%95-%E7%99%BE%E6%99%82%E7%BE%8E%E6%96%BD%E8%B2%B4%E5%AF%B6-%E4%B8%89%E5%AD%A3%E5%A0%B1/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1c2f459b-7b2f-4a83-a1db-e83e523c8307" ["source"]=> string(10) "nai500.com" ["publication_date"]=> string(10) "2023-11-15" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(15) "Market Movement" } } [5]=> array(7) { ["title_en"]=> string(68) "Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript" ["snippet_en"]=> string(212) "Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions." ["url"]=> string(77) "https://finance.yahoo.com/news/arcus-biosciences-inc-nyse-rcus-210527818.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1f99fe4f-1459-40fa-813d-52437fa5b70a" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-11-08" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(8) "Verdicts" [2]=> string(5) "Legal" } } [6]=> array(7) { ["title_en"]=> string(84) "Here’s Why Madison Sustainable Equity Fund Sold Bristol-Myers Squibb Company (BMY)" ["snippet_en"]=> string(252) "Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. As measured by the S&P 500 Index, the markets were mixed in the third quarter." ["url"]=> string(81) "https://finance.yahoo.com/news/why-madison-sustainable-equity-fund-132440530.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/480c36a7-38a1-45e0-9e8b-2da4b9283cc2" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-25" ["categories"]=> array(7) { [0]=> string(18) "General Investment" [1]=> string(22) "Sustainable Investment" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(19) "Investment Requests" [5]=> string(19) "Green & Responsible" [6]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(29) "Billion dollar deal: BMS buys" ["snippet_en"]=> string(182) "Bristol-Myers Squibb (BMS) wants to counteract the threat of patent losses for its top-selling drugs by taking over the cancer drug manufacturer Mirati Therapeutics for $4.8 billion." ["url"]=> string(83) "https://www.apotheke-adhoc.de/nachrichten/detail/markt/milliardendeal-bms-kauft-zu/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/722a49f8-3970-4444-b7ef-63041b14bba0" ["source"]=> string(17) "apotheke-adhoc.de" ["publication_date"]=> string(10) "2023-09-10" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(15) "Deals & Tenders" [2]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(68) "Ossiam Has $4.80 Million Position in Bristol-Myers Squibb (NYSE:BMY)" ["snippet_en"]=> string(214) "Ossiam lowered its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 5.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC)." ["url"]=> string(108) "http://www.defenseworld.net/2023/09/10/ossiam-has-4-80-million-position-in-bristol-myers-squibb-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5ca165dd-5ff4-4d16-9f43-08c31f836ff9" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-09-10" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(11) "Regulations" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(252) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(165) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(153) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(87) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(77) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(75) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(64) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(57) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(55) } [13]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(46) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(46) } [16]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(41) } [19]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(36) } [20]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(34) } [22]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(6) "Energy" ["count"]=> int(22) } [29]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company